This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| ICD-10 code | H35.31 |
|---|---|
| Special Copayment Reduction code | V201 |
| Synonyms / related terms | Exudative macular degeneration, neovascular macular degeneration, wet AMD, macular degeneration associated with choroidal neovascularization (CNV) |
| Classification | Severe intractable disease (Special Copayment Reduction registration criteria: 5 years) |
Age-related macular degeneration (AMD) is a leading cause of blindness in adults aged 50 and older and has been recognized clinically since the late 19th century. In 1855, Karl Stellwag von Carion described changes in the macular region, and in 1875, Jonathan Hutchinson reported a senile retinal disease accompanied by loss of central vision.
Exudative (neovascular) AMD is characterized by choroidal neovascularization (CNV), and the clinical introduction of fluorescein angiography (FA) in the 1970s made CNV visualization possible. In 1982, Gass proposed the classic and occult classification of CNV, and subsequently anti-vascular endothelial growth factor (anti-VEGF) treatments—photodynamic therapy (PDT; 1999), pegaptanib (2004), ranibizumab (2006), bevacizumab (off-label), and aflibercept (2011)—revolutionized the treatment of exudative AMD.
The advent (1991) and development of optical coherence tomography (OCT) made it possible to noninvasively assess fine structures such as subretinal fluid, intraretinal fluid, and pigment epithelial detachment (PED), and it became the standard for diagnosis and monitoring of treatment response.
The etiology of exudative AMD is explained by a complex interaction of environmental factors and genetic susceptibility. The most important environmental risk factors are age (risk rises sharply at 65 and older), smoking (2- to 4-fold increased risk compared with nonsmokers), ultraviolet exposure (including blue light), obesity, hypertension, and cardiovascular disease.
Thickening and degeneration of Bruch's membrane, decreased retinal pigment epithelium (RPE) function, and deposition of drusen form the early lesions of AMD, and subsequently complement overactivation, VEGF overexpression, and oxidative stress jointly induce CNV formation.
VEGF-A is a key factor in CNV formation and increased vascular permeability and is overexpressed in the RPE and Müller cells in response to hypoxia and oxidative stress. Overactivation of the complement pathway (alternative complement pathway) contributes to drusen formation and RPE cell death (apoptosis). Oxidative stress, mitochondrial dysfunction, and lipofuscin accumulation also accelerate RPE damage.
AMD is a strongly heritable polygenic complex disease, and heritability is estimated at about 46-71% in twin studies. GWAS have found more than 30 susceptibility loci, and the strongest genetic risk factors are variants in CFH (complement factor H) and ARMS2/HTRA1.
The Y402H (rs1061170) variant of the CFH gene (1q31.3) reduces the C3b-binding capacity of complement factor H, causing overactivation of the alternative complement pathway, and increases AMD risk about 3-fold. The A69S (rs10490924) variant of the ARMS2 (LOC387715)/HTRA1 locus (10q26) is associated with overexpression of the serine protease HTRA1 and increases the risk of AMD, especially exudative AMD.
Other AMD-associated genes: C3, CFB, CFI, C2 (complement pathway), CETP, LIPC, APOE (lipid metabolism), VEGF (angiogenesis), TIMP3 (tissue inhibitor). The APOE epsilon2 allele increases AMD susceptibility, and epsilon4 acts protectively. The polygenic risk score is used to screen high-risk groups.
AMD is the leading cause of blindness in adults aged 50 and older in developed countries. The worldwide prevalence is estimated at about 190 million in 2020 and is projected to exceed 300 million in 2040. Exudative AMD (H35.31) accounts for about 10-15% of all AMD but about 90% of AMD-related blindness.
In Korean epidemiologic studies, the prevalence of AMD in the population aged 40 and older is about 6-10%, rising sharply with age to exceed 25% at ages 75 and older. The incidence of exudative AMD is estimated at about 50-200 per 100,000 population per year. According to Health Insurance Review & Assessment Service (HIRA) data, AMD patients in Korea number more than 400,000 per year and are increasing.
Smokers have a 2- to 4-fold higher risk of developing AMD than nonsmokers, and the risk decreases gradually after smoking cessation. Epidemiologic differences have been reported: the influence of the ARMS2/HTRA1 genotype is relatively large in Asians, and the influence of CFH Y402H is lower than in Westerners.
The core pathophysiology of exudative AMD is the formation of choroidal neovascularization (CNV), which progresses through the following steps. Reduced oxygen supply due to Bruch's membrane degeneration and RPE dysfunction → activation of HIF-1alpha under hypoxia → overexpression of VEGF-A (especially VEGF165) → endothelial cell proliferation and migration in choroidal vessels → new vessels penetrate Bruch's membrane and grow beneath the RPE (type 1 CNV), above the RPE (type 2 CNV), or within the retina (type 3 CNV; retinal angiomatous proliferation, RAP).
Because new vessels lack the normal blood-retinal barrier, blood components (plasma, red blood cells) leak into the subretinal space and into the retina, leading to intraretinal edema, subretinal fluid, subretinal hemorrhage, and formation of a fibrovascular scar (disciform scar).
Complement-mediated inflammation: Formation of complement C3a, C5a, and the MAC (membrane attack complex) causes RPE cell damage and further VEGF release, creating a vicious cycle. Oxidative stress and phototoxicity due to A2E, a component of lipofuscin, accelerate RPE cell death.
The main symptom of exudative AMD is sudden loss of central vision. Unlike atrophic (dry) AMD, exudative AMD is characterized by rapid visual deterioration within days to weeks. Vision loss is generally monocular, but if lesions are already present in both eyes, or if untreated, the fellow eye may also be affected.
Central scotoma: a scotoma in the center of the visual field, causing difficulty with reading and recognizing faces. Metamorphopsia: a symptom in which straight lines look wavy or distorted, confirmed on Amsler grid self-testing by lines appearing bent.
Other symptoms: decreased contrast sensitivity, delayed dark adaptation, color vision abnormalities, and micropsia or macropsia (objects appearing different in size). Peripheral vision is preserved, so complete loss of vision (darkness) is rare. When macular hemorrhage occurs, sudden and severe loss of central vision may result.
On slit-lamp and fundus examination, the characteristic findings of exudative AMD are a grayish-white or grayish-green subfoveal neovascular membrane, subretinal hemorrhage, exudates (hard exudate), retinal edema, and pigment epithelial detachment (PED). Subretinal hemorrhage arises abruptly from highly vascular CNV and changes from reddish-brown to yellow during absorption.
Fluorescein angiography (FA) findings: Classic CNV is characterized by lacy early hyperfluorescence and late leakage, and occult CNV shows irregular late hyperfluorescence. Indocyanine green angiography (ICGA) is useful for evaluating occult CNV and CNV accompanied by PED.
OCT findings: Intraretinal cystic spaces (intraretinal fluid, IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), the CNV membrane, and others are identified at high resolution. OCT angiography (OCTA) can visualize CNV blood flow without contrast agent and is used to monitor treatment response.
The Amsler grid self-test is the basic tool for self-monitoring of macular disease. While wearing corrective glasses at a distance of about 30 cm and fixating on the central point of the grid, check each eye for distortion, bending, or disappearance of lines. Immediate ophthalmologic care is recommended if metamorphopsia or a new decrease in vision occurs.
Fundus photography: the basic test for recording and tracking drusen, pigment abnormalities, geographic atrophy, and CNV-related changes. Wide-field fundus photography is useful for evaluating peripheral lesions.
OCT is the standard test for AMD diagnosis and evaluation of treatment response, quantitatively tracking changes in retinal thickness, fluid location, and central retinal thickness (CRT). FA and ICGA are performed to confirm CNV type and plan treatment. Genetic testing (CFH, ARMS2/HTRA1) may be performed for research purposes or risk assessment.
Diagnosis of exudative AMD (H35.31) is based on integration of clinical findings and OCT, FA/ICGA/OCTA findings. Diagnostic requirements: ① age 50 or older; ② confirmation of macular CNV (IRF/SRF/PED on OCT, CNV hyperfluorescence and leakage on FA); ③ preceding or accompanying dry AMD (drusen, RPE abnormalities); ④ exclusion of other causes (pathologic myopia, choroidal tumor, ocular trauma, CSCR, etc.).
CNV classification (location and morphology): ① subfoveal, ② juxtafoveal, ③ extrafoveal — response to anti-VEGF treatment can be predicted by location. Morphologic classification: classic, occult, mixed, RAP (retinal angiomatous proliferation). The 2013 neovascular AMD classification (type 1: type 1 MNV, type 2: type 2 MNV, type 3: RAP/type 3 MNV) is widely used.
Special Copayment Reduction (V201) registration requirements: diagnosis certificate from an ophthalmologist, OCT/FA results, and best corrected visual acuity measurement results. Recording best corrected visual acuity (BCVA) and CRT before treatment starts is essential for evaluating future treatment response.
The standard treatment for exudative AMD is intravitreal anti-VEGF injection. Agents currently available in Korea are ranibizumab (Lucentis, 0.5 mg), aflibercept (Eylea, 2 mg), faricimab (Vabysmo, 6 mg; dual blockade of VEGF-A and Ang-2), and brolucizumab (Beovu, 6 mg), and bevacizumab is used off-label.
Dosing protocols: fixed interval (monthly), as needed (pro re nata, PRN), and treat-and-extend (T&E); the T&E protocol has recently been widely adopted in clinical practice. As initial loading treatment, after 3 monthly injections, the dosing interval is adjusted by 2-4 weeks according to the OCT response.
Photodynamic therapy (PDT): verteporfin is used in combination with anti-VEGF when classic CNV predominates. Submacular surgery and radiotherapy are currently considered only in selected cases. Low-vision rehabilitation (magnifiers, electronic assistive devices, eccentric fixation training) is important for maximizing visual function when residual vision loss remains after treatment.
Since the introduction of anti-VEGF treatment, the prognosis of exudative AMD has improved markedly. In the ANCHOR and MARINA studies, about 30-40% of the monthly ranibizumab group showed improved vision, and about 90% were protected from vision loss. The VIEW study confirmed the noninferiority of aflibercept.
Determinants of long-term prognosis: visual acuity at the start of treatment, CNV type (type 1 has a better visual prognosis than type 2), treatment discontinuation and irregular visits, fellow eye involvement, and progression of geographic atrophy. When a fibrovascular scar (disciform scar) has formed, irreversible visual impairment remains.
Risk of fellow eye involvement: When one eye is affected, the incidence of CNV in the fellow eye within 5 years is about 40%, and the risk increases further in those with complement system gene risk factors. Regular follow-up interval: monthly during treatment of active CNV, and after stabilization the interval can be extended up to 16 weeks with the T&E approach.
Exudative AMD cannot be completely prevented, but strategies to delay onset and slow progression are recommended. Smoking cessation is the most important lifestyle improvement for AMD prevention. Weight control, regular aerobic exercise, hypertension management, and blood glucose control are also associated with reduced risk of AMD progression.
AREDS2 supplement (AREDS2 formula): In patients with intermediate or higher-stage AMD or unilateral advanced AMD, a combined supplement of vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg, and copper 2 mg reduces the risk of progression by about 25%. Beta-carotene was excluded because of increased lung cancer risk in smokers.
Wearing UV-blocking glasses (UV-A/B blocking) is recommended. Early detection through regular eye examinations (once a year at age 50 and older, every 6 months for high-risk groups for AMD) and Amsler grid self-monitoring is important. In unilateral advanced AMD, taking AREDS2 and regular monitoring of the fellow eye contribute to early detection of fellow eye CNV.